| pubmed-article:8329571 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8329571 | lifeskim:mentions | umls-concept:C0015518 | lld:lifeskim |
| pubmed-article:8329571 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
| pubmed-article:8329571 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:8329571 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:8329571 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:8329571 | lifeskim:mentions | umls-concept:C0054578 | lld:lifeskim |
| pubmed-article:8329571 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8329571 | pubmed:dateCreated | 1993-8-17 | lld:pubmed |
| pubmed-article:8329571 | pubmed:abstractText | The cysteine proteinase, cancer procoagulant (CP; EC 3.4.22.26) was isolated from human amnion-chorion and purified by precipitation with polyethylene glycol and either ion exchange or immunoaffinity chromatography. A new, sensitive, three-stage chromogenic assay was developed for determination of CP factor X-activating activity. Using this assay some properties including dose-response, effect of calcium, phospholipid and pH on the activation of factor X by CP was determined. There was an excellent linear correlation (r2 = 0.99) between concentration and the enzymatic activity of CP. The activation of factor X by purified CP was calcium dependent with an optimum calcium concentration of 7 mM. CP was not phospholipid dependent. There was a rather broad pH optimum between pH 6.9 and 7.25 for the activation of factor X by CP. | lld:pubmed |
| pubmed-article:8329571 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8329571 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8329571 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8329571 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8329571 | pubmed:issn | 0957-5235 | lld:pubmed |
| pubmed-article:8329571 | pubmed:author | pubmed-author:GordonS GSG | lld:pubmed |
| pubmed-article:8329571 | pubmed:author | pubmed-author:MielickiW PWP | lld:pubmed |
| pubmed-article:8329571 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8329571 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:8329571 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8329571 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8329571 | pubmed:pagination | 441-6 | lld:pubmed |
| pubmed-article:8329571 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:meshHeading | pubmed-meshheading:8329571-... | lld:pubmed |
| pubmed-article:8329571 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8329571 | pubmed:articleTitle | Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. | lld:pubmed |
| pubmed-article:8329571 | pubmed:affiliation | University of Colorado Health Science Center, Denver 80262. | lld:pubmed |
| pubmed-article:8329571 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8329571 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8329571 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8329571 | lld:pubmed |
